Pressure BioSciences Inc. (PBIO)
| Market Cap | 9.03M |
| Revenue (ttm) | 1.22M |
| Net Income (ttm) | -17.58M |
| Shares Out | 4.32M |
| EPS (ttm) | -5.32 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 7 |
| Last Price | $2.00 |
| Previous Close | $2.09 |
| Change ($) | -0.09 |
| Change (%) | -4.31% |
| Day's Open | 2.01 |
| Day's Range | 1.89 - 2.01 |
| Day's Volume | 17,465 |
| 52-Week Range | 1.30 - 3.95 |
Conference Call Scheduled for Wednesday, April 21st at 4:30pm ET SOUTH EASTON, MA / ACCESSWIRE / April 19, 2021 / Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" and the "Company") today announced that ...
Company Expects Acquisition to be Accretive with Sustained Profitable Revenue Growth, Leveraging Market-Changing Synergy from PBI's Ultra Shear Technology Nanoemulsions Platform SOUTH EASTON, MA / ACCES...
About PBIO
Pressure BioSciences, Inc. develops and sells pressure-based platform solutions in the Americas, Europe, Asia, Africa, and Australia. Its pressure cycling technology (PCT) technology uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to control the actions of molecules in biological samples, including cells and tissues from human, animal, plant, and microbial sources. The company offers Barocycler instrumentations comprising Barocycler 2320EXT, Barocycler HUB880, Barocycler HUB440, and The Shredder SG3. It als... [Read more...]
| Industry Medical Devices | IPO Date Oct 31, 1996 |
| Stock Exchange OTCMKTS | Ticker Symbol PBIO |
Financial Performance
In 2020, PBIO's revenue was $1.22 million, a decrease of -32.56% compared to the previous year's $1.81 million. Losses were -$16.01 million, 37.3% more than in 2019.
Analyst Forecasts
The average 12-month stock price forecast for PBIO is 1.57, which is a decrease of -21.50% from the latest price.